Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 5, 2017, Pages 767-775.e3

  Yang, Ju Dong ^a   Larson, Joseph J ^b   Watt, Kymberly D ^a   Allen, Alina M ^a   Wiesner, Russell H ^a   Gores, Gregory J ^a   Roberts, Lewis R ^a   Heimbach, Julie A ^b   Leise, Michael D ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Database; Liver Cancer; LT; UNOS OPTN

Indexed keywords

ADULT; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ARTICLE; DETERIORATION; DONOR SELECTION; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NONALCOHOLIC FATTY LIVER; RELIABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TREND STUDY; UNITED STATES; ADOLESCENT; AGED; LIVER FAILURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; WAITING LISTS; YOUNG ADULT;

EID: 85018645608     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.11.034     Document Type: Article

References (27)

1. 1 Ghabril, M., Charlton, M., Lack of survival benefit following liver transplantation with MELD exception points for hepatocellular carcinoma: beyond the unblinding of lady justice. Gastroenterology 149 (2015), 531–534.
2. 2 Goldberg, D., French, B., Newcomb, C., et al. Patients with hepatocellular carcinoma have highest rates of wait-listing for liver transplantation among patients with end-stage liver disease. Clin Gastroenterol Hepatol 14 (2016), 1638–1642.
3. 3 Yang, J.D., Kim, B., Sanderson, S.O., et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clin Proc 87 (2012), 9–16.
4. 4 Yang, J.D., Roberts, L.R., Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7 (2010), 448–458.
5. 5 Charlton, M.R., Burns, J.M., Pedersen, R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
6. 6 Wong, R.J., Aguilar, M., Cheung, R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
7. 7 van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
8. 8 Pungpapong, S., Aqel, B., Leise, M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
9. 9 Siddiqui, M.S., Charlton, M., Liver transplantation for alcoholic and nonalcoholic fatty liver disease: pretransplant selection and posttransplant management. Gastroenterology 150 (2016), 1849–1862.
10. 10 Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
11. 11 Wedd, J.P., Nordstrom, E., Nydam, T., et al. Hepatocellular carcinoma in patients listed for liver transplantation: current and future allocation policy and management strategies for the individual patient. Liver Transpl 21 (2015), 1543–1552.
12. 12 Alver, S.K., Lorenz, D.J., Marvin, M.R., et al. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates. Liver Transpl 22 (2016), 1343–1355.
13. 13 Heimbach, J.K., Hirose, R., Stock, P.G., et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 61 (2015), 1643–1650.
14. 14 Kim, W.R., Terrault, N.A., Pedersen, R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 137 (2009), 1680–1686.
15. 15 Jang, J.W., Choi, J.Y., Kim, Y.S., et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 61 (2015), 1809–1820.
16. 16 Foster, G.R., Irving, W.L., Cheung, M.C., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
17. 17 Belli, L.S., Berenguer, M., Cortesi, P.A., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 65 (2016), 524–531.
18. 18 Gallegos-Orozco, J.F., Charlton, M.R., Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?. Liver Int 35 (2015), 9–11.
19. 19 Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
20. 20 Burr, A.T., Li, Y., Tseng, J.F., et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg 35 (2011), 1590–1595.
21. 21 Yang, J.D., Aqel, B.A., Pungpapong, S., et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65 (2016), 859–860.
22. 22 Reig, M., Marino, Z., Perello, C., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
23. 23 Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.e1.
24. 24 Flegal, K.M., Carroll, M.D., Kit, B.K., et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307 (2012), 491–497.
25. 25 Pham, T., Dick, T.B., Charlton, M.R., Nonalcoholic fatty liver disease and liver transplantation. Clin Liver Dis 20 (2016), 403–417.
26. 26 Gallegos-Orozco, J.F., Charlton, M.R., Alcoholic liver disease and liver transplantation. Clin Liver Dis 20 (2016), 521–534.
27. 27 Udompap, P., Kim, D., Kim, W.R., Current and future burden of chronic nonmalignant liver disease. Clin Gastroenterol Hepatol 13 (2015), 2031–2041.